Labiana Health (DB:8RK) - Stock Price, News & Analysis

8RK Stock Overview

Develops, manufactures, sells, and markets animal and human health medicine products in Spain, rest of European Union, and internationally. More details

8RK fundamental analysis
Snowflake Score
Valuation	5/6
Future Growth	5/6
Past Performance	0/6
Financial Health	3/6
Dividends	0/6

Rewards

Trading at 90.3% below our estimate of its fair value

Earnings are forecast to grow 98.87% per year

Revenue grew by 10.1% over the past year

Trading at good value compared to peers and industry

Risk Analysis

Does not have a meaningful market cap (€15M)

Volatile share price over the past 3 months compared to the German market

Labiana Health, S.A. Competitors

Biofrontera

XTRA:B8FK

€17.0m

SynBiotic

DUSE:SBX

€29.9m

Cantourage Group

XTRA:HIGH

€53.9m

Redx Pharma

DB:0RX

€65.0m

Price History & Performance

Summary of all time highs, changes and price drops for Labiana Health
Historical stock prices
Current Share Price	€1.99
52 Week High	€3.06
52 Week Low	€0.94
Beta	-0.31
11 Month Change	-14.22%
3 Month Change	-32.31%
1 Year Change	84.26%
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	-15.32%

Recent updates

Shareholder Returns

	8RK	DE Pharmaceuticals	DE Market
7D	5.3%	-10.1%	-1.5%
1Y	84.3%	-21.6%	7.9%

Return vs Industry: 8RK exceeded the German Pharmaceuticals industry which returned -24.1% over the past year.

Return vs Market: 8RK exceeded the German Market which returned 8.3% over the past year.

Price Volatility

Is 8RK's price volatile compared to industry and market?
8RK volatility
8RK Average Weekly Movement	8.0%
Pharmaceuticals Industry Average Movement	6.8%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	11.0%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: 8RK's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: 8RK's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

Founded	Employees	CEO	Website
1958	364	Manuel Ortega	www.labiana.com

Labiana Health, S.A. develops, manufactures, sells, and markets animal and human health medicine products in Spain, rest of European Union, and internationally. The company offers anesthetics-sedative, anti-infective, anti-inflammatory, antiparasitic, hormonal, and nutritional products; metabolism regulators; and vitamin products. It also provides sterile, lyophilized, and biological formats; and Fosfomycin trometamol under the Fosfomicina Labiana brand name.

Labiana Health, S.A. Fundamentals Summary

How do Labiana Health's earnings and revenue compare to its market cap?
8RK fundamental statistics
Market cap	€15.07m
Earnings (TTM)	-€1.18m
Revenue (TTM)	€66.14m

0.2x

P/S Ratio

-12.8x

P/E Ratio

Is 8RK overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
8RK income statement (TTM)
Revenue	€66.14m
Cost of Revenue	€28.10m
Gross Profit	€38.03m
Other Expenses	€39.21m
Earnings	-€1.18m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.17
Gross Margin	57.51%
Net Profit Margin	-1.78%
Debt/Equity Ratio	885.5%

How did 8RK perform over the long term?

See historical performance and comparison

Labiana Health DB:8RK Stock Report